A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC).
E. M. O' Reilly, G. Abou-Alfa, R. Letourneau, W. Harker +6 more
2004Journal of Clinical Oncology71 citations
Semantic Scholar

